DC-SCRIPT Antibodies

204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 7 days and 1 µg/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) for last 24 hours were stained with Human DC-SCRIPT/ZNF366 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4707, filled histogram), or control antibody (Catalog # AB-108-C, open histogram), followed by Donkey Anti-Goat IgG (H+L) Phycoerythrin (Catalog # F0107). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_lightbox"> 204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 7 days and 1 µg/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) for last 24 hours were stained with Human DC-SCRIPT/ZNF366 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4707, filled histogram), or control antibody (Catalog # AB-108-C, open histogram), followed by Donkey Anti-Goat IgG (H+L) Phycoerythrin (Catalog # F0107). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="Human mature dentritic cells differentated from human peripheral blood mononuclear cell derived CD14⁺cells treated with 20 ng/mL Recombinant Human IL-4 (Catalog # 204-IL) and 50 ng/mL Recombinant Human GM-CSF (Catalog # 215-GM) for 7 days and 1 µg/mL LPS, 20 ng/mL Recombinant Human TNF-a (Catalog # 210-TA), and 20 ng/mL Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) for last 24 hours were stained with Human DC-SCRIPT/ZNF366 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4707, filled histogram), or control antibody (Catalog # AB-108-C, open histogram), followed by Donkey Anti-Goat IgG (H+L) Phycoerythrin (Catalog # F0107). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />